Lilly’s diabetes med Trulicity shrugs off Novo Nordisk chall...

Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus

Novo’s new oral GLP-1 Rybelsus still has obstacles to overco...

Novo Nordisk hints at US price cuts after Q2 sales fall

Danish pharma Novo Nordisk posted second-quarter operating profit in line with forecasts but hinted about the possibility of cutting the price of some drugs on the US market next year.

Trulicity helps SGLT-2 patients lower blood sugar

New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.

Novo Nordisk undeterred after losing out on Ablynx takeover

After losing out to Sanofi in its pursuit of Belgian biotech Ablynx earlier this week, Novo Nordisk has put a brave face on the disappointment.